MHRA publishes rare therapies and UK regulatory considerations

The Medicines and Healthcare Products Regulatory Agency (MHRA) has published a new paper announcing its intention to overhaul the ‘rulebook’ for rare disease therapies in the UK. Titled: “Rare therapies and UK regulatory considerations,” the paper sets out the UK’s ambition to become a global leader in developing, regulating and integrating therapies for rare diseases […]